Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Bin Zhang has been with Cytovance as a member of the Board of Directors since 2018.
November 12, 2020
By: Contract Pharma
Contract Pharma Staff
Cytovance Biologics, a biopharmaceutical contract development and manufacturing organization (CDMO) of mammalian and microbial biologics, has appointed Bin Zhang as chief executive officer. Zhang served two months as Interim CEO before this formal appointment by the board to CEO. He will report to Mr. Li Li, founder and chairman of the Board for Shenzhen Hepalink Pharmaceutical Group Co. Ltd. and member of the Board for Cytovance. Zhang has been with Cytovance as a member of the Board of Directors since 2018. In this role as CEO, he will provide oversight in the implementation of the company’s business strategies in the innovative drug development and contract manufacturing market. “It is an honor to work with the talented Cytovance team more closely than my board member role,” Zhang commented. “Cytovance has made tremendous progress since the Hepalink acquisition in 2015. With the trust of our clients, the hard work of all Cytovance staff and the additional investment made by Hepalink after the acquisition, we have strengthened our core services in both capacity and scope and entered into commercial stage manufacture. The board of Cytovance and Hepalink are both committed to make additional investments in Cytovance to better serve our clients and ultimately to bring well-being to patients around the world.” Zhang will also continue to serve as the financial controller for Hepalink where his primary responsibilities include participating in decision-marking in respect of business operation strategies and overseeing the business strategy and financial activities of Hepalink. He holds a Master of Business Administration and serves on the board of other subsidiaries within Hepalink.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !